@article{10902/23773,
year = {2021},
url = {http://hdl.handle.net/10902/23773},
abstract = {Nowadays, a number of promising strategies are being developed that aim at combining diagnostic and therapeutic capabilities into clinically effective formulations. Thus, the combination of a modified release provided by an organic encapsulation and the intrinsic physico-chemical properties from an inorganic counterpart opens new perspectives in biomedical applications. Herein, a biocompatible magnetic lipid nanocomposite vehicle was developed through an efficient, green and simple method to simultaneously incorporate magnetic nanoparticles and an anticancer drug (doxorubicin) into a natural nano-matrix. The theranostic performance of the final magnetic formulation was validated in vitro and in vivo, in melanoma tumors. The systemic administration of the proposed magnetic hybrid nanocomposite carrier enhanced anti-tumoral activity through a synergistic combination of magnetic hyperthermia effects and antimitotic therapy, together with MRI reporting capability. The application of an alternating magnetic field was found to play a dual role, (i) acting as an extra layer of control (remote, on-demand) over the chemotherapy release and (ii) inducing a local thermal ablation of tumor cells. This combination of chemotherapy with thermotherapy establishes a synergistic platform for the treatment of solid malignant tumors under lower drug dosing schemes, which may realize the dual goal of reduced systemic toxicity and enhanced anti-tumoral efficacy.},
organization = {This work was partially supported by NORTE 2020 (2014–2020 North Portugal Regional Operational Program), and the ERDF (European Regional Development Fund) under Grant NORTE-01-0145-FEDER-000019, by European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 686009, by “TAMs-targeted and externally controlled nanotheranostics of triple-negative-breast-cancer (Nanother)" project UTAPEXPL/NTec/0038/2017, by “Local specific treatment of triple-negativebreast-cancer through externally triggered target-less drug carriers (MagtargetON)" project NORTE-01-0145-FEDER-031142, co-funded by FCT and the ERDF through NORTE2020, and by 2014–2020 INTERREG Cooperation Programme Spain–Portugal (POCTEP) through the Project 0624_2IQBIONEURO_6_E. Co-authors also acknowledge support from Raman4clinics COST Action BM1401 and Radiomag COST action TD1402. ML-F also acknowledges the ERDF and the Spanish MINECO under project ref. PI19/00349 (AES 2019). LGH thanks the Instituto de Salud Carlos III for the Sara Borrell Grant (CD19/00035).},
publisher = {Ke Ai Publishing},
publisher = {Bioactive Materials, 2021, 17(8), 153-164},
title = {Magnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma theranostics},
author = {García-Hevia, Lorena and Casafont Parra, Íñigo and Oliveira, Jessica and Terán Villagrá, Nuria and López Fanarraga, Mónica and Gallo, Juan and Bañobre-López, Manuel},
}